Martin Lindberg-Larsen1,2, Anders Odgaard3, Charlotte Fredborg4, Henrik Morville Schrøder5. 1. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. martin.lindberg-larsen@rsyd.dk. 2. Orthopaedic Research Unit, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense, Denmark. martin.lindberg-larsen@rsyd.dk. 3. Department of Orthopaedic Surgery and Traumatology, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark. 4. Intensive Care Unit, Copenhagen University Hospital Rigshospitalet-Glostrup, Copenhagen, Denmark. 5. Department of Orthopaedic Surgery, Næstved Hospital, Næstved, Denmark.
Abstract
BACKGROUND: A two-stage prosthesis exchange procedure has been the gold standard in surgical treatment of the chronically infected knee arthroplasty so far. This includes 2 surgeries/hospitalizations and an interim period of 2-3 months between surgeries with impaired health, functional status and quality of life of the patients. A one-stage exchange procedure holds many obvious advantages compared to the two-stage approach, but outcomes of a one-stage versus two-stage procedures have never been investigated in a randomized clinical trial. The purpose of this study is primarily to investigate time-adjusted differences in functional status of patients after one-stage versus two-stage revision. Secondary, to report time-adjusted differences in quality of life, complications (including re-revisions due to infection) and mortality. METHODS: This study is a pragmatic, multi-center, randomized, non-inferiority trial comparing one-stage versus two-stage revision of the infected knee arthroplasty. Seven Danish hospitals are currently participating in the study, but additional hospitals can enter the study if adhering to protocol. Ninety-six patients will be included prospectively. Follow-up will be with PROM-questionnaires and clinical controls up to 10 years. The patients who are not able to participate in the randomized trial are followed in a parallel cohort study. PROM'S: Oxford Knee Score and EQ5D + EQ5DVAS questionnaires are completed preoperatively and sent out to the study participants at 6 weeks, 3, 6, 9, 12, 18 and 24 months as well as 5 and 10 years postoperatively. In addition a tailor made cost questionnaire on the non-treating hospital resource use, community health and social service use, travel costs, time off work and informal care are sent out. DISCUSSION: If one of the two treatment alternatives is found superior in both domains of quality of life (both knee-specific and generic) and health economics, that treatment should be promoted. Other outcomes will open informed discussions about treatment strategies for periprosthetic knee infections. TRIAL REGISTRATION: The randomized trial is registered on ClinicalTrials.gov with ID NCT03435679 , initial release date January 31, 2018 and the cohort study is registered with ID NCT04427943 , submitted January 8, 2020 and posted June 11, 2020.
RCT Entities:
BACKGROUND: A two-stage prosthesis exchange procedure has been the gold standard in surgical treatment of the chronically infected knee arthroplasty so far. This includes 2 surgeries/hospitalizations and an interim period of 2-3 months between surgeries with impaired health, functional status and quality of life of the patients. A one-stage exchange procedure holds many obvious advantages compared to the two-stage approach, but outcomes of a one-stage versus two-stage procedures have never been investigated in a randomized clinical trial. The purpose of this study is primarily to investigate time-adjusted differences in functional status of patients after one-stage versus two-stage revision. Secondary, to report time-adjusted differences in quality of life, complications (including re-revisions due to infection) and mortality. METHODS: This study is a pragmatic, multi-center, randomized, non-inferiority trial comparing one-stage versus two-stage revision of the infected knee arthroplasty. Seven Danish hospitals are currently participating in the study, but additional hospitals can enter the study if adhering to protocol. Ninety-six patients will be included prospectively. Follow-up will be with PROM-questionnaires and clinical controls up to 10 years. The patients who are not able to participate in the randomized trial are followed in a parallel cohort study. PROM'S: Oxford Knee Score and EQ5D + EQ5D VAS questionnaires are completed preoperatively and sent out to the study participants at 6 weeks, 3, 6, 9, 12, 18 and 24 months as well as 5 and 10 years postoperatively. In addition a tailor made cost questionnaire on the non-treating hospital resource use, community health and social service use, travel costs, time off work and informal care are sent out. DISCUSSION: If one of the two treatment alternatives is found superior in both domains of quality of life (both knee-specific and generic) and health economics, that treatment should be promoted. Other outcomes will open informed discussions about treatment strategies for periprosthetic knee infections. TRIAL REGISTRATION: The randomized trial is registered on ClinicalTrials.gov with ID NCT03435679 , initial release date January 31, 2018 and the cohort study is registered with ID NCT04427943 , submitted January 8, 2020 and posted June 11, 2020.
Authors: David J Beard; Kristina Harris; Jill Dawson; Helen Doll; David W Murray; Andrew J Carr; Andrew J Price Journal: J Clin Epidemiol Date: 2014-10-31 Impact factor: 6.437
Authors: Morten Schmidt; Sigrun Alba Johannesdottir Schmidt; Jakob Lynge Sandegaard; Vera Ehrenstein; Lars Pedersen; Henrik Toft Sørensen Journal: Clin Epidemiol Date: 2015-11-17 Impact factor: 4.790
Authors: Simon Strange; Michael R Whitehouse; Andrew D Beswick; Tim Board; Amanda Burston; Ben Burston; Fran E Carroll; Paul Dieppe; Kirsty Garfield; Rachael Gooberman-Hill; Stephen Jones; Setor Kunutsor; Athene Lane; Erik Lenguerrand; Alasdair MacGowan; Andrew Moore; Sian Noble; Joanne Simon; Ian Stockley; Adrian H Taylor; Andrew Toms; Jason Webb; John-Paul Whittaker; Matthew Wilson; Vikki Wylde; Ashley W Blom Journal: Trials Date: 2016-02-17 Impact factor: 2.279
Authors: Mustafa Akkaya; Georges Vles; Iman Godarzi Bakhtiari; Amir Sandiford; Jochen Salber; Thorsten Gehrke; Mustafa Citak Journal: Int Orthop Date: 2022-01-04 Impact factor: 3.075
Authors: Argyris C Hadjimichael; Athanasios F Foukas; Angelos Kaspiris; Dimitris Vasileiou; Spyros Kamariotis; Antonios Stylianakis; Elias S Vasiliadis; Olga D Savvidou; Athanasios Antonopoulos Journal: Infect Prev Pract Date: 2022-07-12